Melinta Therapeutics
Gold Member
Can you share a brief summary of what your company does and how that fits into the home & alternate site infusion industry?
Melinta Therapeutics is a biopharmaceutical company dedicated to providing innovative therapies to people impacted by acute and life-threatening illnesses. We focus our expanding portfolio on therapeutic areas with unmet needs to make the greatest possible impact on patients. Through collaboration with healthcare providers, we ensure that the patients who need our therapies receive them.
What are you most looking forward to at NHIA 2025?
We look forward to connecting with our industry colleagues and customers at NHIA 2025.
What are the biggest challenges your customers are currently facing?
Medicare’s payment structure for home-based care continues to be a hurdle for patients’ access to these services. NHIA’s proposed legislation with the Preserving Patient Access to Home Infusion Act would provide a solution to this challenge.
What are you most excited to share with attendees at the conference?
We are excited to discuss our portfolio of anti-infective medications and how they can help appropriate patients get the treatments they need.
